Skip to content

Kansai-based Clinic Combining Cancer Immunotherapy,
Hyperthermia & Reductive Electron Therapy

Reservations & Inquiries by PhoneTEL.072-640-0170
Outside of clinic hours, an answering machine will respond.

3F Goda C&E Building, 2-13-14 Kamikorori, Ibaraki City, Osaka 567-0065

Cancer Immunotherapyimmunotherpy

Cancer Immunotherapy

Dendritic Cell Injection Therapy (DCI Therapy)

What Are Dendritic Cells?
Dendritic cells phagocytose pathogens such as cancer cells and bacteria; they then present portions of these as antigens to T cells and release cytokines that further activate the T cells.
In other words, dendritic cells initiate the immune response and direct it toward its target — they can be regarded as central commanders of the immune system.
In Dendritic Cell Intratumoral Injection Therapy, cells called monocytes are extracted, treated with cytokines, and artificially differentiated and expanded into dendritic cells with strong phagocytic capability.
These dendritic cells are injected directly into the tumor lesion, where they phagocytose cancer cells and absorb tumor information. They then migrate through the lymphatic vessels to the lymph nodes, transmitting the absorbed cancer antigens to Killer T lymphocytes and others, prompting an attack on the tumor.

Treatment Flow
Blood (80–100 ml) is drawn, and monocytes are isolated using a special method. IL-4 and GM-CSF are then added, and the cells are cultured for approximately one week.
The culture medium is then removed and the cells washed; the harvested dendritic cells are loaded into a syringe and injected into the tumor lesion.


It takes approximately one week from blood draw to injection into the tumor lesion.

Treatment Duration & Frequency
 Duration  1.5–3 months
 Frequency The number of sessions is determined through consultation with the physician.
.

Risks & Side Effects
As immune cell therapy uses the patient's own immune cells, mild fever or rash may occur in some cases, but no other side effects are observed, and there is minimal burden on the body.
Because side effects are extremely rare, treatment can be continued while maintaining quality of life.

Treatment Outcomes at Our Clinic
We have many cases of tumor shrinkage on CT imaging, improved tumor markers, and improved QOL. The combination of DCI (dendritic cells) and LAK (activated lymphocytes) is highly strategic, with many effective cases.